Unresolved issues in implantable cardioverter-defibrillator therapy.
Over the last 15 years, a series of well-designed randomized clinical trials has clearly demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces mortality in select high-risk populations. Despite the widespread acceptance of ICD therapy, many questions related to its optimal use remain. This article discusses several key issues now confronting clinicians.